Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico
On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.
MGC And GlycoNex Kick Off Denosumab Trial In Japan
Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.
Neuraxpharm Brings In Greek Olanzapine Brand
CNS specialist Neuraxpharm has snapped up the Lazap olanzapine brand in Greece from local firm Lyofin, helping to further expand its presence in the Greek market following a recent acquisition.
Dr Reddy’s Takes Another Step Forward On Tocilizumab
Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.
Zydus Looks To NASH Trials In Turkey, Generic Vascepa Launch In The US
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter.
Generics Bulletin Explains: Sandoz’s Spinoff From Novartis
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
Indoco Builds On Recent Growth With Acquisition In US
Indoco says it has marked a major milestone with a $4m deal to take a controlling stake in US firm Florida Pharmaceutical Products, strengthening the Indian company’s position in the US market.
Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China
Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.
Sandoz Reveals New Headquarters Post Spin, Mid-2024 Date Outlined
Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.